Think of Lancora as a Niche Drug for Heart Failure
Lancora (LAHN-core-ah, ivabradine) will be a new option for treating systolic heart failure. It's marketed as Corlanor in the U.S.
It works by inhibiting the If or "funny" current in the heart. This lowers heart rate...withOUT causing a drop in blood pressure.
Ivabradine prevents one in 25 patients from being hospitalized over 2 years...when ADDED to an ACEI or ARB, beta-blocker, and aldosterone antagonist. But it DOESN'T reduce overall mortality.